Iron Supplementation for Restless Legs Syndrome

Introduction to Iron Formulation

• The American Academy of Sleep Medicine recommends achieving adequate elemental iron delivery and correcting the underlying iron deficiency based on RLS-specific ferritin thresholds, with no specific iron preparation being absolutely required 1, 2

Iron Formulation Recommendations

• The American Academy of Sleep Medicine conditionally recommends ferrous sulfate for patients with ferritin ≤75 ng/mL or transferrin saturation <20%, based on limited RCT data showing efficacy 2
• Oral iron absorption is poor when ferritin >50-75 ng/mL, making it less effective in this range compared to IV formulations 2
• Common side effects of oral iron include constipation, which may limit tolerability 2

Intravenous Iron Formulations

• The American Academy of Sleep Medicine provides a strong recommendation for IV ferric carboxymaltose (1000 mg) with moderate certainty of evidence for patients with ferritin ≤75 ng/mL or transferrin saturation <20% 1
• The American Academy of Sleep Medicine conditionally recommends IV low molecular weight iron dextran with very low certainty of evidence 1
• The American Academy of Sleep Medicine conditionally recommends IV ferumoxytol based on limited observational data 1, 2

RLS-Specific Iron Thresholds

• The American Academy of Sleep Medicine recommends supplementing iron if ferritin ≤75 ng/mL or transferrin saturation <20% in adults 1
• For adults with ferritin 75-100 ng/mL, the American Academy of Sleep Medicine recommends using IV iron only (not oral) 1, 2
• For children, the American Academy of Sleep Medicine recommends supplementing iron if ferritin <50 ng/mL 1

Testing Requirements Before Treatment

• The American Academy of Sleep Medicine mandates checking serum ferritin and transferrin saturation in all patients with clinically significant RLS 1
• Testing should be done in the morning after avoiding iron-containing supplements and foods for at least 24 hours 1, 3

Treatment Algorithm Based on Iron Status

• For ferritin ≤75 ng/mL or transferrin saturation <20%, the American Academy of Sleep Medicine recommends starting with oral ferrous sulfate (65 mg elemental iron) or considering IV ferric carboxymaltose as first-line treatment 2
• For ferritin 75-100 ng/mL, the American Academy of Sleep Medicine recommends using IV iron only (oral iron poorly absorbed in this range) 1, 2
• For ferritin >100 ng/mL, iron supplementation is generally not indicated based on current evidence 1

Why Formulation Matters for IV Iron

• The pharmacology of slow-release, higher-dose formulations (ferric carboxymaltose, ferumoxytol, low molecular weight iron dextran) enables H-ferritin binding and macrophage iron uptake necessary for CNS penetration, unlike fast-release formulations like iron sucrose 2

Common Pitfalls to Avoid

• The American Academy of Sleep Medicine advises against using general population ferritin cutoffs (<15-30 ng/mL) for RLS, as higher thresholds are required 1, 2
• The American Academy of Sleep Medicine advises against assuming all IV iron formulations are equivalent, as iron sucrose lacks efficacy except in dialysis patients 2
• The American Academy of Sleep Medicine advises against forgetting to test iron studies before treatment, as this is a good practice statement requirement 1
• The American Academy of Sleep Medicine advises against testing iron studies while the patient is taking supplements, and recommends waiting 24 hours after the last iron-containing product 1

Best Iron Preparation for Restless Leg Syndrome Infusion

Introduction to Iron Therapy for RLS

• The American Academy of Sleep Medicine recommends ferric carboxymaltose as the preferred formulation for adults with RLS requiring intravenous iron therapy, with a strong recommendation and moderate certainty of evidence 4, 5, 6

Strength of Recommendation by IV Iron Formulation

• Ferric carboxymaltose receives a strong recommendation with moderate certainty of evidence, making it the only IV iron formulation with this level of support, based on 5 randomized controlled trials demonstrating clinically significant improvements in disease severity, sleep quality, and quality of life 4, 5, 6, 7
• The evidence base for ferric carboxymaltose includes moderate effect sizes and acceptable safety profiles, with no significant increase in study withdrawals due to adverse events 7
• Adverse events leading to study withdrawal did not meet clinical significance, with the main risks being hypophosphatemia and dizziness 7

Second-Line Options

• Low molecular weight iron dextran receives a conditional recommendation with very low certainty of evidence, based on just 1 observational study 4, 5, 7
• Ferumoxytol similarly receives a conditional recommendation with very low certainty of evidence, based on 1 RCT without a placebo arm 4, 5, 7

Not Recommended for General RLS Population

• Iron sucrose failed to show clinically significant benefit over placebo in high-quality studies for general RLS patients 8
• Iron sucrose only receives a conditional recommendation specifically for patients with end-stage renal disease who have ferritin <200 ng/mL and transferrin saturation <20% 9

Why Ferric Carboxymaltose is Superior

• Slow-release, higher-dose formulations like ferric carboxymaltose enable H-ferritin binding and macrophage iron uptake necessary for CNS penetration 8
• Fast-release, low-dose formulations like iron sucrose lack the necessary pharmacology to deliver iron effectively to the central nervous system 8

When to Use IV Iron vs. Oral Iron

• Either oral ferrous sulfate or IV ferric carboxymaltose can be used as first-line for patients with ferritin ≤75 ng/mL or transferrin saturation <20% 4, 5, 7
• Oral iron receives a conditional recommendation with moderate certainty for patients with ferritin ≤75 ng/mL or transferrin saturation <20% 5, 7

Critical Testing Requirements Before Treatment

• All patients with clinically significant RLS must have serum ferritin and transferrin saturation checked before initiating any iron therapy, with blood drawn in the morning after fasting and avoiding iron-containing supplements and foods for at least 24 hours before blood draw 4

Common Pitfalls to Avoid

• RLS requires higher ferritin thresholds (≥75 ng/mL) than the general population (<15-30 ng/mL) 4, 5, 6, 7
• Only ferric carboxymaltose has strong evidence in RLS, and iron sucrose lacks efficacy except in dialysis patients 4, 5, 6, 7, 8
• Check serum phosphate levels in patients requiring repeat courses of treatment, especially if within 3 months, to monitor for hypophosphatemia 7

Iron Therapy Guidelines for Restless Legs Syndrome (RLS)

Assessment and Testing Requirements

• Obtain serum ferritin and transferrin saturation in all patients with clinically significant RLS as a mandatory good‑practice statement from the American Academy of Sleep Medicine (strong recommendation) 10.
• Draw blood in the morning after the patient has avoided all iron‑containing supplements and foods for at least 24 hours to ensure accurate iron studies (moderate certainty) 10.
• Do not perform iron studies while the patient is taking iron supplements; wait ≥ 24 hours after the last iron‑containing product (moderate certainty) 10.

Laboratory Thresholds Guiding Iron Therapy

First‑Line Iron Formulations

• IV ferric carboxymaltose 1000 mg single infusion is the only IV iron formulation with a strong recommendation and moderate certainty of evidence for adult RLS (based on five RCTs showing improvements in disease severity, sleep quality, and quality of life) (American Academy of Sleep Medicine) 10.
• Low‑molecular‑weight iron dextran receives a conditional recommendation with very low certainty (supported by one observational study) (American Academy of Sleep Medicine) 10.
• Ferumoxytol receives a conditional recommendation with very low certainty (supported by one RCT without a placebo arm) (American Academy of Sleep Medicine) 10.
• Iron sucrose is not recommended for the general RLS population; it has a conditional recommendation only for end‑stage renal disease (ESRD) patients with ferritin < 200 ng/mL and TSAT < 20% (moderate certainty) (American Academy of Sleep Medicine) 10.

Concomitant Pharmacologic Therapy

• Gabapentinoids (gabapentin, gabapentin enacarbil, pregabalin) are first‑line pharmacologic agents for RLS and may be started concurrently with iron supplementation (moderate certainty) 10.
• Dopamine agonists (pramipexole, ropinirole, rotigotine) should not be used as first‑line therapy because they carry a 7‑10 % annual risk of augmentation (moderate certainty) 10.
• Other agents lacking evidence or with safety concerns (cabergoline, bupropion, carbamazepine, clonazepam, valproic acid) should be avoided (moderate certainty) 10.

Special Populations

• Pediatric patients: Initiate iron therapy when ferritin < 50 ng/mL (lower threshold than adults). Oral ferrous sulfate receives a conditional recommendation with very low certainty (American Academy of Sleep Medicine) 10.
• Pregnancy: Oral iron formulations are preferred throughout gestation due to a favorable safety profile (moderate certainty) 10.
• End‑Stage Renal Disease: Use IV iron sucrose (not ferric carboxymaltose) when ferritin < 200 ng/mL and TSAT < 20%; the higher ferritin cutoff reflects altered iron metabolism in ESRD (moderate certainty) 10.

Monitoring and Follow‑Up

• IV ferric carboxymaltose may require up to 12 weeks to achieve full clinical benefit; significant improvement is typically observed by week 12 (moderate certainty) 10.
• Oral iron: reassess symptoms and repeat iron studies after 3 months; if ineffective or not tolerated, switch to IV ferric carboxymaltose (moderate certainty) 10.
• During ongoing therapy, monitor ferritin and transferrin saturation every 6‑12 months; consider checking serum phosphate after repeat IV iron courses to detect hypophosphatemia (moderate certainty) 10.

Laboratory Assessment and Iron Supplementation Guidelines for Restless Legs Syndrome

Pre‑Treatment Laboratory Assessment

• Baseline serum ferritin and transferrin saturation must be measured in all patients with clinically significant RLS, with blood drawn in the morning after at least a 24‑hour iron‑free interval. This is a good practice statement from the American Academy of Sleep Medicine with a strong recommendation. 11

• Electrolytes and renal function tests are required before starting iron therapy; in patients with chronic kidney disease, a higher ferritin threshold of < 200 ng/mL is used to decide on iron supplementation. Recommendation originates from the American Academy of Sleep Medicine. 11

Special Populations

End‑Stage Renal Disease (ESRD)

• For ESRD patients, iron supplementation is guided by a ferritin cutoff of < 200 ng/mL and a transferrin saturation threshold of < 20 %. These thresholds reflect the altered iron metabolism in this population and are endorsed by the American Academy of Sleep Medicine. 11

• Intravenous iron sucrose (rather than ferric carboxymaltose) is the preferred formulation for ESRD patients who meet the above criteria. Guidance provided by the American Academy of Sleep Medicine. 11

Pediatric Patients

• In children with RLS, a lower ferritin threshold of < 50 ng/mL is used to determine the need for iron therapy. This recommendation is from the American Academy of Sleep Medicine. 11